Collectively, our findings elucidate another metabolic liability in KL co-mutant lung cancer, PGM3 dependence, and explore how PGM3 inhibition (e.g., FR054) can be used to exploit this vulnerability. This evidence concerns the gene KL and lung carcinoma.